Dexbrompheniramine Maleate 6 Mg and Pseudoephedrine Sulfate 120 Mg Extended-Release Tablets

Total Page:16

File Type:pdf, Size:1020Kb

Dexbrompheniramine Maleate 6 Mg and Pseudoephedrine Sulfate 120 Mg Extended-Release Tablets Newtown, PA 18940 MADE IN USA IN MADE 18940 PA Newtown, Newtown, PA 18940 U.S.A. 18940 PA Newtown, 6014/03 6014/00 Manufactured by KVK-TECH, INC KVK-TECH, by Manufactured Manufactured by KVK-TECH, INC., KVK-TECH, by Manufactured COLD & ALLERGY & COLD carton COLD, ALLERGY & DECONGESTANT & ALLERGY COLD, D recyclable CA Extended-release Tablets Extended-release and Pseudoephedrine Sulfate 120 mg 120 Sulfate Pseudoephedrine and ® Dexbrompheniramine Maleate 6 mg 6 Maleate Dexbrompheniramine 20 EXTENDED-RELEASE TABLETS EXTENDED-RELEASE EXP.: LOT: parahydroxy benzoate, sodium lauryl sulfate, sucrose, talc, titanium dioxide, triethyl citrate microcrystalline cellulose, pharmaceutical ink, polysorbate 80, povidone, pregelatinized starch, propyl lactose monohydrate, magnesium stearate, methacrylic acid copolymer, methyl parahydroxybenzoate, aluminum lake, FD&C blue No. 1 yellow 6 gelatin, hypromellose, Inactive ingredients Drug Facts Questions? Runny Nose, Sneezing Nose, Runny Call 1-215-579-1842 (continued) tion - Conges Sinus & Nasal calcium sulfate, carnauba wax, colloidal silicon dioxide, D&C yellow No. 10 Maximum Maximum CA Dexbrompheniramine Maleate 6 mg and Pseudoephedrine Sulfate 120 mg Extended-release Tablets COLD & ALLERGY & COLD NASAL DECONGESTANT-Pseudoephedrine NASAL COLD & ALLERGY Dexbrompheniramine ANTIHISTAMINE- Antihistamine/Nasal Decongestant Antihistamine/Nasal - D DECAAAAAAAAAAAAAAA & ALLERGY COLD, D CA Extended-release Tablets Extended-release ® and Pseudoephedrine Sulfate 120 mg 120 Sulfate Pseudoephedrine and maize Relief Sustained Hour ® 2 1 Dexbrompheniramine Maleate 6 mg 6 Maleate Dexbrompheniramine PSEUDOEPHEDRINE SULFATE... 120 mg IS TORN OR MISSING OR TORN IS mg 120 SULFATE... PSEUDOEPHEDRINE IMPRINTED WITH DEXBROMPHENIRAMINE MALEATE... 6 mg AND AND mg 6 MALEATE... DEXBROMPHENIRAMINE WITH IMPRINTED IS TORN OR MISSING. OR TORN IS COLD & ALLERGY & COLD Relief COLD, ALLERGY & DECONGESTANT & ALLERGY COLD, Sustained SAFETY SEALED: DO NOT USE IF BACKING ON BLISTER CARD CARD BLISTER ON BACKING IF USE NOT DO SEALED: SAFETY D ALLERGY & DECONGESTANT DECONGESTANT & ALLERGY CA Extended-release Tablets Extended-release Hour IMPRINTED WITH CAD WITH IMPRINTED COLD, COLD, ® 2 1 120 mg 120 and Pseudoephedrine Sulfate Pseudoephedrine and IF BACKING ON BLISTER CARD CARD BLISTER ON BACKING IF ® SAFETY SEALED: DO NOT USE USE NOT DO SEALED: SAFETY 6 mg 6 Dexbrompheniramine Maleate Dexbrompheniramine Dexbrompheniramine ®Maleate 6 mg Drug Facts (continued) and Pseudoephedrine Sulfate 120 mg Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis Extended-release Tablets glaucoma heart disease high blood pressure thyroid disease CAD COLD,COLD ALLERGY & ALLERGY & DECONGESTANT diabetes trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or Drug Facts tranquilizers Active ingredients (in each tablet) Purpose When using this product do not use more than directed▀▀▀▀▀▀▀▀▀▀▀ Dexbrompheniramine maleate 6 mg ........................... Antihistamine excitability may occur, especially in children Pseudoephedrine sulfate 120 mg ......................... Nasal decongestant drowsiness may occur avoid alcoholic beverages Uses alcohol, sedatives and tranquilizers may increase drowsiness temporarily relieves nasal congestion due to the common cold, use caution when driving a motor vehicle or operating machinery hay fever or other upper respiratory allergies, and associated Stop use and ask a doctor if with sinusitis nervousness, dizziness or sleeplessness occur helps decongest sinus openings and sinus passages symptoms do not improve within 7 days or occur with a reduces swelling of nasal passages, shrinks swollen membranes, feverYou may report side effects to FDA at 1-800-FDA 1088 and temporarily restores freer breathing through the nose If pregnant or breast-feeding, ask a health professional before use. temporarily alleviates the following symptoms due to hay fever Keep out of reach of children. In case of overdose, get medical help (allergic rhinitis): or contact a Poison Control Center right away. runny nose sneezing itching of the nose or throat itchy and watery eyes Directions adults and children 12 years and over: 1 tablet every 12 hours. Do not exceed 2 tablets in 24 hours. Warnings children under 12 years of age: ask a doctor Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, Other information each tablet contains: calcium 69 mg psychiatric or emotional conditions, or Parkinson’s disease), store between 2 0 � to 2calcium5�C with 69 mg and or for 2 weeks after stopping the MAOI drug. If you do not know sodiumexcursions 0 mg permitted between (68° to 77°F) if your prescription drug contains an MAOI, ask a doctor or 15� to 30�C (59� to 86�F)[see USP pharmacist before taking this product. Controlled Room Temperature]. Version# 1 4-25-06 5-1-06 *ALL COLORS CREATE 11-14-06 4/CPRO FROM 4/C PROCESS 11-27-06 11-27-06(2) KVK TECH CAD KVK5110620 xxxx xxx PO#xxx Drug Facts (continued) Uses Inactive Ingredients: Questions? Call 1-215-579-1842. 2 . 1088 - FDA - 800 - Dexbrompheniramine Maleate 6 mg 1 and Pseudoephedrine Sulfate 120 mg Extended-release Tablets Antihistamine/ Nasal Decongestant COLD & ALLERGY LOT: DO NOT USE. PUSH TABLET THROUGH BACKING THROUGH TABLET PUSH USE. NOT DO Manufactured By: EXP: , KVK-TECH, INC. Contains FD&C No. 6. Yellow Newtown, PA 18940 USA 6126/02 MADE IN USA Call your doctor for medical advice about side effects. side about advice medical for your doctor Call at FDA to effects side may report You IF BACKING HAS BEEN TORN --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- ROBERT L WEST 02/27/2013 Deputy Director, Office of Generic Drugs, for Gregory P. Geba, M.D., M.P.H. Reference ID: 3267870.
Recommended publications
  • MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted
    MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • Medications to Be Held for Allergy Skin Testing
    Your appointment with Dr. Jill Poole, Dr. Sara May or Dr. Andrew Rorie Dr. Joel VanDeGraaff is scheduled for: _______________________ MEDICATIONS TO BE HELD FOR ALLERGY SKIN TESTING ANTIHISTAMINES (TO BE HELD FOR 5 DAYS): Clarinex (desloratidine) Claritin (loratidine) Allegra (fexofenadine) Chlor-Trimeton (chlorpheneramine) Dexchlorpheniramine Benadryl (diphenhydramine) Zyrtec (cetirizine) Xyzal (levocetirizine) Brovex (brompheniramine) Dimetapp Actifed Periactin (cyproheptadine) Drixoral (dexbrompheniramine) Please check your over the counter medications to see if they include an antihistamine EYE DROPS (TO BE HELD FOR 5 DAYS): Bepreve (bepotastine) Zaditor (ketotifen) Optivar (azelastine) Patanol/Pataday/Pazeo (olopatadine) All over the counter eye drops with antihistamine-A TOPICAL STEROID ANTI-INFLAMMATORIES (TO BE HELD FOR 5 DAYS): (Gels, Creams, Ointments, Solutions, and Lotions) ORAL PREDNISONE Ideally off oral steroids for two weeks; however, skin testing can be completed while on oral steroid use at less than 20 mg daily. ANTIDEPRESSANTS (TO BE HELD FOR 1-2 WEEKS AS APPROVED WITH PCP): Elavil (amitryptiline) Doxepin Trimipramine Desipramine Remeron (mirtazapine) Trazodone Serzone (nefazodone) Asendin (amoxapine) Pamelor (nortriptyline) Imipramine NASAL SPRAYS (TO BE HELD FOR 5 DAYS): Astelin (azelastine) Patanase (olopatadine) Astelin/Astepro (azelastine) Dymista HISTAMINE BLOCKERS (TO BE HELD FOR 1 DAY): Tagamet (cimetidine) Zantac (ranitidine) Axid (nizatidine) Pepcid (famotidine) OTHERS (TO BE HELD THE NIGHT BEFORE): Singulair (montelukast) Zyflo (zileuton) Accolate (zafirlukast) OTHERS (TO BE HELD 4-7 DAYS BEFORE): Vistaril/Atarax (hydroxyzine) Phenergan (promethazine) Xanax (alprazolam) Klonopin (clonazepam) Flexeril (cyclobenzaprine) Antivert/Bonine (meclizine) Tylenol Cold & Sinus *If you have any questions, please call 402-559-4015 and ask to speak to a Allergy nurse. .
    [Show full text]
  • UQ272429 OA.Pdf
    Cochrane Database of Systematic Reviews Oral antihistamine-decongestant-analgesic combinations for the common cold (Review) De Sutter AIM, van Driel ML, Kumar AA, Lesslar O, Skrt A De Sutter AIM, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD004976. DOI: 10.1002/14651858.CD004976.pub3. www.cochranelibrary.com Oral antihistamine-decongestant-analgesic combinations for the common cold (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 3 OBJECTIVES ..................................... 3 METHODS ...................................... 4 RESULTS....................................... 5 Figure1. ..................................... 7 Figure2. ..................................... 8 DISCUSSION ..................................... 19 AUTHORS’CONCLUSIONS . 20 ACKNOWLEDGEMENTS . 20 REFERENCES ..................................... 21 CHARACTERISTICSOFSTUDIES . 24 DATAANDANALYSES. 64 Analysis 1.1. Comparison 1 Combination 1: Antihistamine-decongestant, Outcome 1 Global evaluation. 66 Analysis 1.2. Comparison 1 Combination 1: Antihistamine-decongestant, Outcome 2 Side effects: all - Combination 1: Antihistamine-decongestant. 67 Analysis 1.3. Comparison 1 Combination 1: Antihistamine-decongestant,
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 209089Orig1s000 209090Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209089Orig1s000 209090Orig1s000 CLINICAL REVIEW(S) CLINICAL REVIEW Application Type NDA (Rx to OTC switch) Application Number(s) 209-089 Xyzal Allergy 24 HR tablets 209-090 Xyzal Allergy 24 HR solution Priority or Standard Standard Submit Date(s) March 18, 2016 Received Date(s) March 31, 2016 PDUFA Goal Date January 31, 2017 Division / Office DPARP/ODE 2/OND Reviewer Name(s) Xu Wang, M.D., Ph.D. Review Completion Date December 9, 2016 Established Name Levocetirizine dihydrochloride Rx Trade Name Xyzal tablets/solution OTC Trade Name Xyzal Allergy 24HR tablets/solution Therapeutic Class Antihistamine Applicant UCB Inc. Formulation(s) tablets/solution Dosing Regimen ≥12 years: One tablet (5 mg) daily/10 mL solution (5 mg) daily; 1 6 – 11 years: /2 tablet (2.5 mg) daily/5 mL solution (2.5 mg) daily; 2 – 5 years: 2.5 mL solution (1.25 mg) daily Indication(s) Temporarily relieve these symptoms due to hay fever or other upper respiratory allergies: • running nose, • sneezing, • itchy, watering eyes, • itching of nose or throat Intended Population(s) Tablets: ≥6 years of age Solution: ≥2 years of age Template Version: March 6, 2009 Reference ID: 4025819 Clinical Review Xu Wang, M.D., Ph.D. NDA 209-089/NDA 209-090 Rx to OTC switch Xyzal Allergy 24HR (levocetirizine dihydrochloride) tablets/solution Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT .........................................4 1.1 Recommendation on Regulatory Action ............................................................. 4 1.2 Risk Benefit Assessment .................................................................................... 4 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 4 2.1 Product Information ............................................................................................ 4 2.2 Currently Available Treatments for Proposed Indications..................................
    [Show full text]
  • Allergy Skin Testing Instructions
    2073 N. Clybourn Ave, Chicago, IL 60614 T 773.665.4016 / F 773.360.6200 ALLERGY SKIN TESTING INSTRUCTIONS Allergy skin testing provides a fast, safe and reliable means for identifying allergic sensitivities to inhalant allergens (e.g., pollens, molds, dust mites and animal danders) and is also used sometimes to diagnose allergic sensitivities to foods and sometimes antibiotics and insect stings. The information obtained from allergy testing provides guidance for avoidance of allergens and potential medication choices. Test results may also be used to formulate allergy shot extracts. In order to make your allergy testing appointment as productive as possible, we ask that you review the following instructions prior to your appointment: 1. Although the testing itself may be completed in one hour or less, additional time may be needed to discuss results, allergy avoidance measures, medications or allergy shot treatments. 2. Wear a shirt or blouse, which can be removed easily. Prick skin testing is performed using the Multitest™ device applied to the back. 3. Many medications interfere with allergy skin testing and many do not. Below you will find a list of both. Those that do interfere should be discontinued in the time specified. If you have a medical condition or severe allergic symptoms which might worsen without medications, please consult us prior to stopping these medications. We can often find a way to work around such problems. If you have forgotten to stop these medications by the specified time, please consult one of our nurses to determine whether or not you need to reschedule your allergy testing appointment.
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratidine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratidine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]
  • These Medications Should Not Be Taken at Least 14 Days Before Skin Testing**
    **THESE MEDICATIONS SHOULD NOT BE TAKEN AT LEAST 14 DAYS BEFORE SKIN TESTING** Prescription and Over the Counter Nasal Sprays Antihistamines Accuhist (brompheniramine) Astelin (azelastine) Actifed (chlorpheniramine) Patanase (olopatadine) Advil Allergy Sinus Astepro (azelastine) Alavert (loratadine) Dymista Allegra/Allegra D (fexofenadine) AlleRx (chlorpheniramine Eye Drops Atarax/Vistaril (hydroxyzine) Bepreve (bepotastine) Benadryl (diphenhydramine) Elestat (epinastine) Biohist LA (chlorpheniramine) Naphcon-A (pheniramine) Bromfed/Bromfed PD (brompheniramine) Optivar (azelastine) Chlor-Trimeton (chlorpheniramine) Pataday (olopatadine) Claritin/Claritin D (loratadine) Patanol (olopatadine) Clarinex/Clarinex D (desloratadine) Visine-A (pheniramine) Deconamine/Naldecon (chlorpheniramine) Zaditor (Ketotifen) Dimetane (brompheniramine) Alaway Dimetapp (brompheniramine) Donatussin (carbinoxamine) Non-Prescription Sleep Aids Histex (brompheniramine) Advil PM (diphenhydramine) Histussin D/Histussin HC (Dexbrompheniramine) Nytol (diphenhydramine) Nalex-A (chlorpheniramine, phenyltoloxamine) Tylenol PM (diphenhydramine) Nyquil (doxylamine) Unisom (doxylamine) Palgic/Palgic-D (carbinoxamine) Pancof HC (chlorpheniramine) Antacid Medications Pannaz (carbinoxamine, methscopolamine) Axid (nizatidine) Periactin (cyproheptadine) Pepcid (famotidine) Polaramine (dexchlorpheniramine) Tagment (cimetadine) Poly-Histine (pheniramine, pyrilamine, Zantac (ranitidine) phenyltoloxamine) Rescon (chlorpheniramine) Respa-AR (chlorpheniramine) Anti-nausea/Anti-vertigo
    [Show full text]